Genotype-Phenotype Correlations, Dystonia and Disease Progression in Spinocerebellar Ataxia Type 14

Viorica Chelban, MD, MSc, MRCP,1,2,3 Sarah Wiethoff, MD, PhD,1,4 Bjørn K. Fabian-Jessing, MD,5 Nourelhoda A. Haridy, MD,1,6 Alaa Khan, MSc,1 Stephanie Efthymiou, MSc,1 Esther B. E. Becker, PhD, MSc,7 Emer O’Connor, MD, MRCP1,1,8 Suzanne G. Lindquist, MD, PhD,9,10 Michael B. Petersen, MD,9 Jørgen E. Nielsen, MD,9 Michael Nielsen, MD,11 Nicholas W. Wood, MD,1,2 Paola Giunti, MD,12 and Henry Houlden, MD1,2*

1Department of Molecular Neuroscience, University College London, Institute of Neurology, London, UK
2National Hospital for Neurology and Neurosurgery, London, UK
3Department of Neurology and Neurosurgery, Institute of Emergency Medicine, Chisinau, Republic of Moldova
4Center for Neurology and Heritie Institute for Clinical Brain Research, Eberhard-Karls-University, Tübingen, Germany
5Department of Clinical Genetics, Aalborg University Hospital, Aalborg, Denmark
6Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
7Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark
8Danish Dementia Research Centre, Neurogenetics Clinic, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
9Department of Clinical Genetics, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
10Department of Neurology, Aalborg University Hospital, Aalborg, Denmark
11Department of Molecular Neuroscience, Ataxia Centre UCL, Institute of Neurology, London, UK

ABSTRACT: Background: Spinocerebellar ataxia type 14 is a rare form of autosomal dominant cerebellar ataxia caused by mutations in protein kinase Cγ gene. Clinically, it presents with a slowly progressive, mainly pure cerebellar ataxia.
Methods: Using next generation sequencing, we screened 194 families with autosomal dominant cerebellar ataxia and normal polyglutamine repeats. In-depth pheno-otyping was performed using validated clinical rating scales neuroimaging and electrophysiological investigations.
Results: We identified 25 individuals from 13 families carrying pathogenic mutations in protein kinase Cγ gene. A total of 10 unique protein kinase Cγ gene mutations have been confirmed of which 5 are novel and 5 were previously described. Our data suggest that the age at onset is highly variable; disease course is slowly progressive and rarely associated with severe disability. However, one third of patients presented with a complex ataxia comprising severe focal and/or task-induced dystonia, peripheral neuropathy, parkinsonism, myoclonus, and pyramidal syndrome. The most complex phenotype is related to a missense mutation in the catalytic domain in exon 11.
Conclusion: We present one of the largest genetically confirmed spinocerebellar ataxia type 14 cohorts contributing novel variants and clinical characterisation. We show that although protein kinase Cγ gene mutations present mainly as slowly progressive pure ataxia, more than a third of cases had a complex phenotype. Overall, our case series extends the phenotype and suggests that protein kinase Cγ gene mutations should be considered in patients with slowly progressive autosomal dominant cerebellar ataxia, particularly when myoclonus, dystonia, or mild cognitive impairment are present in the absence of polyglutamine expansion. © 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Key Words: PRKCG; SCA14; dystonia; ataxia; genetics
Autosomal dominant cerebellar ataxias are a heterogeneous group of neurodegenerative disorders. Spinocerebellar ataxia type 14 (SCA14) is a very rare form with an estimated incidence of 1% to 4% of all autosomal dominant cerebellar ataxias.1,2 It is caused by mutations in the protein kinase Cγ gene (PRKCG). Missense mutations are responsible for most of SCA14 reported cases but deletions and splicing variants have also been described.3,4 The mutations are primarily located in the regulatory domains C1 and C2, with C1 harboring the largest cluster of pathogenic PRKCG variants.5 PRKCG is expressed predominantly in Purkinje cells. Neurodegeneration in SCA14 is thought to result from defective aggregation and disrupted synaptic activity.6,7 Clinically, SCA14 presents with slowly progressive, early-onset, mainly pure cerebellar ataxia.8 Some complex ataxic phenotypes have been associated with PRKCG mutations, including focal, task-induced dystonia, myoclonus, and pyramidal syndrome in single cases or small cohorts.1,9 We describe the genetic and clinical analysis of one of the largest genetically confirmed SCA14 cohorts contributing novel variants and supporting the phenotypic heterogeneity of PRKCG mutations.

**Methods**

**Subjects**

Proband cases with autosomal dominant, mainly pure, cerebellar ataxia were recruited with informed consents. Most of the families were of European ancestry (n = 194, of which 190 were British, 3 Danish, and 1 Italian). All cases had comprehensive phenotyping performed by neurogenetics specialists. Ataxia was quantified in 17 cases using the validated Scale for Assessment and Rating of Ataxia (SARA).10 Pure phenotype was defined as cerebellar syndrome, with brisk reflexes and neurogenic bladder accepted as additional features. Complex phenotype was defined as cases with cerebellar syndrome, plus at least 1 other neurological sign that cannot be explained by associated comorbidities. Disability score was defined as follows: 0 = asymptomatic, 1 = able to walk but difficulty with running, 2 = uses one stick and/or orthosis, 3 = uses 2 sticks/walker, 4 = unable to walk, uses wheelchair.

Results from additional investigations were analyzed where available: neuroimaging with brain magnetic resonance imaging (MRI; n = 12), fluoro(deoxy)glucose (FDG)-positron emission tomography (PET) (n = 2), electromyogram or nerve conduction studies (n = 7), and videography. The cases with symptomatic memory/cognitive complaints (n = 5) had formal cognitive assessment performed by qualified neuropsychiatrists.

**Genetic Testing**

DNA was extracted and investigated under approval of the joint ethics committee of UCL Institute of Neurology and the National Hospital for Neurology and Neurosurgery, London, UK (UCLH: 04/N034). Families IX and XIII were tested with informed consent as part of a clinical diagnostic evaluation (Centogene AG, Rostock, Germany and Molecular Genetic Laboratory, Department of Clinical Genetics, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark). Apart from 2 families (IX and XIII), the SCA1, 2, 3, 6, 17, Frataxin (FXN)-repeat expansions, Junctophilin 3 (JPH3), and common DNA polymerase gamma (POLG)-mutations were excluded in all cases using standard diagnostic techniques. Ataxia-telangiectasia mutated gene (ATM) kinase activity and levels of radiation-induced chromosome damage as well as aprataxin and senataxin levels were normal in all complex cases.

In the research approach, a custom-sequencing panel was designed to amplify the coding exons of PRKCG using the Illumina Truseq custom amplicon kit following the manufacturer’s protocol. Libraries were prepared according to the standard protocols and then sequenced using an Illumina MiSeq. Bioinformatics analysis included alignment of reads to the hg19 genome build using Novoalign (Novocraft, Selangor, Malaysia) and variant calling using SAMtools (http://samtools.sourceforge.net/). Variant annotation was performed with ANNOVAR,11 and coverage metrics were assessed using an in-house modified Bedtools coverageBed script. After mutation identification, all of the variants reported here were confirmed using Sanger sequencing.

For every identified PRKCG mutation, we determined pathogenicity and novelty. Novel and very rare (minor allele frequency <0.1%), coding/splicing, and heterozygous variants that are predicted to be pathogenic were considered as likely causal variants.12,13 For the missense variants, the prediction was based on conservation across different species and assessing novel amino acid changes in known pathogenic positions. Where possible, segregation was confirmed in other family members.

**Statistical Analysis**

Two-tailed t-tests were used to assess the correlation between disease duration and SARA score. \( P \leq .05 \) was considered statistically significant.

**Results**

**Genetic Analyses**

From the 194 index cases, a total of 13 pathogenic mutations in PRKCG (ENST00000263431) were confirmed. We identified 10 unique mutations, of which 5 were novel and 5 known pathogenic variants (Fig. 1A). A total of 9 mutations were unique to 1 kindred
### A.

| Case number | cDNA     | Amino acid change | Consequence | Known/novel | Location |
|-------------|----------|-------------------|-------------|-------------|----------|
| I-1         | c.70G>A  | p.Ala24Thr        | Missense    | Novel       | Exon 1   |
| II-1        | c.76A>G  | p.Arg26Gly        | Missense    | Known       | Exon 1   |
| III-1       | c.220C>T | p.His74Tyr        | Missense    | Known       | Exon 1   |
| IV-1        | c.303C>G | p.His101Gln       | Missense    | Known       | Exon 4   |
| V-1         | c.303C>G | p.His101Gln       | Missense    | Known       | Exon 4   |
| VI-1        | c.317A>C | p.His106Pro       | Missense    | Novel       | Exon 4   |
| VII-1       | c.413T>A | p.Val138Glu       | Missense    | Known       | Exon 5   |
| VIII-1      | c.1372G>A| p.Ala458Thr       | Missense    | Novel       | Exon 11  |
| IX-1        |          |                   |             |             |          |
| IX-2        |          |                   |             |             |          |
| IX-3        | c.392G>A | p.Cys131Tyr       | Missense    | Known       | Exon 4   |
| IX-4        |          |                   |             |             |          |
| IX-5        |          |                   |             |             |          |
| X-1         | c.302A>G | p.His101Arg       | Missense    | Novel       | Exon 4   |
| XI-1        | c.303C>G | p.His101Gln       | Missense    | Known       | Exon 4   |
| XII-1       | c.303C>G | p.His101Gln       | Missense    | Known       | Exon 4   |
| XIII-1      |          |                   |             |             |          |
| XIII-2      |          |                   |             |             |          |
| XIII-3      | c.424T>G | p.Cys142Gly       | Missense    | Novel       | Exon 5   |
| XIII-4      |          |                   |             |             |          |
| XIII-5      |          |                   |             |             |          |
| XIII-6      |          |                   |             |             |          |

### B.

FIG. 1. Description of mutations identified in spinocerebellar ataxia type 14 (SCA14) cohort. (A) Description of all protein kinase Cγ gene (PRKCG) mutations identified in the study (ENST00000263431). (B) Schematic representation of the PRKCG gene with the mutations identified in our study. The exons are represented approximately to scale. The introns are represented by a blue line between exons. The PRKCG protein’s regulatory functional domains are indicated: blue = cysteine-rich region C1 (cys1 and cys2); orange = Ca^{2+} sensitive region (C2); purple = the catalytic domain containing kinase (C3) and substrate recognition (C4) regions. The novel mutations are indicated on the top and the known mutations on the bottom of the figure. [Color figure can be viewed at wileyonlinelibrary.com]
The most frequent mutation was the previously reported c.303C>G (p.His101Gln) found in 4 of our families. Three mutations were located in exon 1, 4 mutations in exon 4, and 2 mutations in exon 5 as part of the regulatory domains C1a and C1b. One mutation was located in the catalytic domain in exon 11 of PRKCG (Fig. 1B). All variants were missense mutations.

Case VIII-1 had a novel heterozygous mutation c.1372G>A (p.Ala458Thr) confirmed by Sanger sequencing (Fig. 2A-C). This mutation is located at a highly conserved amino acid position (Fig. 2D). In silico tools predict disease-causing effects (Mutation Taster, http://www.mutationtaster.org/) and a highly likely protein function interference (Align-GVD, http://agvgd.iarc.fr/) with a Combined Annotation Dependent Depletion (http://cadd.gs.washington.edu/home) score of 22.3 and a Genomic Evolutionary Rate Profiling score of 3.4 (Fig. 2E). No other family members were available for further testing.

Family XIII is a large Danish family with 6 affected individuals. As part of a clinical diagnostic evaluation, a novel heterozygous mutation in exon 5, the c.424T>G (p.Cys142Gly) was identified. The mutation fully segregated with the disease in the family. This mutation is absent from all publicly available databases.
Case I-1 has a novel heterozygous change c.70A>G (p.Ala24Thr) that segregated with disease in the family. This change is located in a highly conserved amino acid position in the regulatory C1a domain. Family VI and family X presented novel amino acid changes in known pathogenic positions c.317A>C (p.His106Pro) and c.302A>G (p.His101Arg), respectively.

The other cases had previously described pathogenic mutations in PRKCG that segregated with the disease.

**Clinical Summary**

SCA14 individuals included in our cohort presented with variable disease onset and phenotype. The mean age of onset was 30.6 years with a range from 3 to 66 years, revealing a high variability between and within the families. Within families, an earlier onset was observed in the offspring of affected parents; however, we attribute this to recall and ascertain bias. An early age of onset (defined as onset before 20 years of age) was identified in 40% of cases. However, a late onset (after the age of 50) was reported in 12% of cases (3/25; Fig. 3A). Mean disease duration was 18 years (range 1-52 years). The mean SARA score at the last examination (for 17 cases with a SARA score) was 13.1, consistent with moderate severity. SARA scores correlated positively with disease duration \( (P = 0.02; \text{Fig. 3B}) \), but not with age of onset. Disease onset was related to gait or limb ataxia. Table 1 presents the results of detailed clinical examination. Screening for atypical features revealed a complex ataxia phenotype in 36% (9/25) of cases presenting with ataxia and 1 additional neurological sign or combination of signs, including severe focal dystonia, task-induced dystonia, severe peripheral neuropathy, parkinsonism, myoclonus, tremor, and pyramidal syndrome. Importantly, cases VIII-1 and II-2 presented with the most complex phenotypes (Supporting Information Videos 1 and 2).

**Complex Phenotypes in SCA14**

Case VIII-1 developed a slowly progressive ataxia with onset in the mid-30s initially affecting dexterity and gait. Cerebellar ataxia was associated with dysarthria, mild neurogenic bladder, slight forgetfulness, and clumsiness of hands. At the age of 55 years, he noted new intermittent shaking of his head. This dystonic head tremor rapidly progressed toward severe, constant dystonic posturing of the head and right hand. Currently, his clinical findings consist of dystonic head tremor with constant titubation of head at rest, laterocollis to the left, and subsequent hypertrophy of the right sternocleidomastoid associated with the underlying progressive cerebellar syndrome. A bilateral mild wasting of the small hand muscles is noted together with absent reflexes and severe peripheral neuropathy in the lower limbs (Supporting Information Video 1). Nerve conduction studies showed a severe length-dependent axonal sensory motor neuropathy and a muscle biopsy was suggestive.
| Case number/phenotype | I-1 | II-1 | II-2 | III-1 | IV-1 | V-1 | VI-1 | VI-2 | VI-3 | VII-1 | VIII-1 | IX-1 | IX-2 | IX-3 | IX-4 | IX-5 |
|-----------------------|-----|------|------|-------|------|-----|------|------|------|-------|-------|------|------|------|------|------|
| **Age at onset (years)** |     |      |      |       |      |     |      |      |      |       |       |      |      |      |      |      |
| 40                   | 7   | 20   | 64   | 18    | 20   | 34  | 18   | 35   | 66   | 46    | 96    | 42   | 33   |
| **Symptom at onset**  |     |      |      |       |      |     |      |      |      |       |       |      |      |      |      |      |
| Gait ataxia          | Gait ataxia | Gait ataxia | Gait ataxia | Gait ataxia | Gait ataxia | Gait ataxia | Gait ataxia | Gait ataxia | Gait ataxia | Gait ataxia | Gait ataxia | Gait ataxia | Gait ataxia | Gait ataxia | Gait ataxia |
| **Disease duration** |     |      |      |       |      |     |      |      |      |       |       |      |      |      |      |      |
| 10                   | 36  | 38   | 15   | 16    | 51   | 50  | 12   | 10   | 52   | 26    | 10    | 23   | 2    | 21   | 2    |
| **SWA score**        |     |      |      |       |      |     |      |      |      |       |       |      |      |      |      |      |
| 10                   | 22  | 18   | 6    | 16    | 11   | 22.5| 8    | 14   | 17   | 22    | NA    | NA   | NA   | 11   | 6    |
| **Phenotype**        | Pure | Pure | Complex | Pure | Pure | Pure | Pure | Pure | Pure | Complex | Pure | Pure | Pure | Complex |
| **Limb ataxia**      | +   | +    | +     | +     | +    | +   | +    | +    | +    | +     | +     | +    | +    |
| **Eye signs**        | Nystagmus | Nystagmus | Nystagmus | Nystagmus | Nystagmus | Nystagmus | Nystagmus | Nystagmus | Nystagmus | Nystagmus | Nystagmus | Nystagmus | Saccadic pursuit | Nystagmus | Saccadic pursuit |
| **Dysarthria**       | +   | +    | +     | +     | +    | +   | +    | +    | +    | +     | +     | +    | +    |
| **Pyramidal syndrome** | --  | --   | +     | --    | +    | +   | +    | +    | +    | --    | +     | --   | --   |
| **Parkinsonism**     | --  | --   | Gait freezing, bradykinesia |
| **Cystathia**        | --  | --   | --    | --    | --   | --  | --    | --    | --    | --    | --    | Writer's cramp |
| **Myoclonus**        | --  | --   | Mild, peri-oral facial myoclonus |
| **Peripheral neuropathy** | --  | --   | --    | --    | --   | --  | --    | --    | --    | --    | --    | --    | --    |
| **Other**            | Mild ataxia | --   | Neurogenic bladder | --    | --   | --  | --    | --    | --    | --    | --    | --    | --    |
| **Cerebellar atrophy on MRI** | Mild | Moderate | Moderate | Mild | NA | Mild | Moderate | NA | NA | Mild | Moderate | NA | NA | Moderate | Mild | Mild |
| **NCV/TMG**          | NA  | Normal | Normal | Normal | NA | Normal | Normal | NA | NA | Normal | Severe axonal length dependent neuropathy |
| **Neuropsychology**  | NA  | NA | Mild cognitive dysfunction affecting anterior and subcortical functions | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | Normal |
| Case number/Phenotype | X | XI | XII | XIII-1 | XIII-2 | XIII-3 | XIII-4 | XIII-5 | XIII-6 |
|----------------------|---|----|-----|--------|--------|--------|--------|--------|--------|
| Age at onset (years) | 31| 43 | 28  | 39     | 40     | 6      | 6      | 30     | 3      |
| Symptom at onset     | Gait ataxia| Gait ataxia| Gait ataxia| Gait and balance impairment| Gait impairment| Upper limbs postural tremor followed by gait and balance impairment| Limb ataxia| Balance impairment/ tremor/limb ataxia| Limb ataxia|
| Disease duration     | 12| 8  | 12  | 15     | 6      | 51     | 23     | 6      | 1      |
| SARA score           | NA| NA | NA  | 9.5    | 10     | 12     | NA     | 9      | NA     |
| Disability           | 2 | 2  | 2   | 1      | 1      | 1      | 1      | 1      | 1      |
| Phenotype            | Pure| Pure| Pure| Complex| Complex| Complex| Complex| Complex| Complex|
| Limb ataxia          | + | +  | +   | +      | +      | +      | +      | +      | +      |
| Eye signs            | Nystagmus| Nystagmus| Nystagmus| Broken-up pursuit| Unstable pursuit| Broken-up pursuit| Slow pursuit| Broken-up pursuit| –      |
| Dystonia             | + | +  | +   | +      | +      | +      | –      | +      | +      |
| Pyramidal syndrome   | – | –  | –   | –      | –      | –      | –      | –      | –      |
| Parkinsonism         | – | –  | –   | –      | –      | –      | –      | –      | –      |
| Dystonia             | – | –  | –   | –      | –      | –      | –      | –      | –      |
| Pyramidal syndrome   | – | –  | –   | –      | –      | –      | –      | –      | –      |
| Myoclonus            | – | –  | –   | –      | –      | –      | –      | –      | –      |
| Peripheral neuropathy| – | –  | –   | –      | –      | –      | –      | –      | –      |
| Other                | – | –  | –   | –      | –      | –      | –      | –      | –      |
| Cerebellar atrophy on MRI | NA| NA | NA  | NA     | NA     | NA     | NA     | NA     | NA     |
| NCS/EMG              | NA| NA | NA  | NA     | NA     | NA     | NA     | NA     | NA     |
| Neuropsychology      | NA| NA | NA  | NA     | NA     | NA     | NA     | NA     | NA     |
| EMG, electromyogram; NA, not available; +, present; -, absent; SARA score, Scale for Assessment and Rating of Ataxia score; LL, lower limb; UL, upper limb; NCS, nerve conduction studies. |
**TABLE 2.** Description of all reported mutations affecting the catalytic domain of protein kinase Cγ gene (PRKCG) with the genotype-phenotype correlation

| PHRED4 mutations | p.Gly360Ser | p.Ser361Gly | p.Ala458Thr (this study) | p.Asp480Tyr | p.Phe643Leu | p.Arg659Ser | p.Val692Gly | p.Met697Ile | p.Val771fs |
|------------------|-------------|-------------|--------------------------|-------------|-------------|-------------|-------------|-------------|-------------|
| **Type of mutation** | Missense | Missense | Missense | Missense | Missense | Missense | Missense | Missense | Missense |
| **Conservation** | Highly conserved | Highly conserved | Highly conserved | Highly conserved | Highly conserved | Highly conserved | Highly conserved | Highly conserved | Highly conserved |
| **Zygosity** | Heterozygous | Heterozygous | Heterozygous | Homozygous | Heterozygous | Heterozygous | Heterozygous | Heterozygous/Homozygous | Heterozygous |
| **Penetrance** | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| **Age of onset (years)** | 53 | 5-60 | 35 | NA | Childhood to 60 | Not available | 20 | 7-60 | Not available |
| **Symptom at onset** | Ataxia | Ataxia | Ataxia | Ataxia | Ataxia | Ataxia | Ataxia | Ataxia | Ataxia |
| **Clinical syndrome** | Complex, slowly progressive | Complex, slowly progressive | Complex, slowly progressive | Complex, slowly progressive | Complex, slowly progressive | Complex, slowly progressive | Complex, slowly progressive | Complex, slowly progressive | Complex, slowly progressive |
| **Associated features** | Cognitive decline (8 cases), decreased vibration sense in lower limbs (4 cases), chorea in the hands and head tremor (2 cases), reduced vibration sense in the limbs (1 case), tremor in the limbs (4 cases), mild sensory loss in the limbs (4 cases), reduced vibration sense in the hands and head tremor (1 case), decreased vibration sense in the lower limbs (1 case) | Depression | Dysarthria, head tremor with occasional truncal jerks in case II-2 | Decreased vibration sense | Ataxia | Ataxia | Ataxia | Ataxia | Ataxia |
| **MRI of the brain** | MRI of the brain was available in 14 cases and showed mild to moderate cerebellar atrophy in all cases. | MRI of the brain was available in 14 cases and showed mild to moderate cerebellar atrophy in all cases. | MRI of the brain was available in 14 cases and showed mild to moderate cerebellar atrophy in all cases. | MRI of the brain was available in 14 cases and showed mild to moderate cerebellar atrophy in all cases. | MRI of the brain was available in 14 cases and showed mild to moderate cerebellar atrophy in all cases. | MRI of the brain was available in 14 cases and showed mild to moderate cerebellar atrophy in all cases. | MRI of the brain was available in 14 cases and showed mild to moderate cerebellar atrophy in all cases. | MRI of the brain was available in 14 cases and showed mild to moderate cerebellar atrophy in all cases. | MRI of the brain was available in 14 cases and showed mild to moderate cerebellar atrophy in all cases. |
| **FDG metabolic activity in the cerebellum** | MRI showed metabolic activity in the cerebellum. | MRI showed metabolic activity in the cerebellum. | MRI showed metabolic activity in the cerebellum. | MRI showed metabolic activity in the cerebellum. | MRI showed metabolic activity in the cerebellum. | MRI showed metabolic activity in the cerebellum. | MRI showed metabolic activity in the cerebellum. | MRI showed metabolic activity in the cerebellum. | MRI showed metabolic activity in the cerebellum. |
| **Neuropsychometric testing** | Neuropsychometric testing was performed in 3 individuals (XIII-3, XIII-4, and XIII-5) as well as case IX-5. The 2 affected individuals from a large SCA14 family (XIII-3, XIII-4) also reported cognitive dysfunction with difficulties in concentration and memory. Case XIII-3 is 57 years old. No other cases had cognitive problems identified or reported during clinical examination and follow-up. | Neuropsychometric testing was performed in 3 individuals (XIII-3, XIII-4, and XIII-5) as well as case IX-5. The 2 affected individuals from a large SCA14 family (XIII-3, XIII-4) also reported cognitive dysfunction with difficulties in concentration and memory. Case XIII-3 is 57 years old. No other cases had cognitive problems identified or reported during clinical examination and follow-up. | Neuropsychometric testing was performed in 3 individuals (XIII-3, XIII-4, and XIII-5) as well as case IX-5. The 2 affected individuals from a large SCA14 family (XIII-3, XIII-4) also reported cognitive dysfunction with difficulties in concentration and memory. Case XIII-3 is 57 years old. No other cases had cognitive problems identified or reported during clinical examination and follow-up. | Neuropsychometric testing was performed in 3 individuals (XIII-3, XIII-4, and XIII-5) as well as case IX-5. The 2 affected individuals from a large SCA14 family (XIII-3, XIII-4) also reported cognitive dysfunction with difficulties in concentration and memory. Case XIII-3 is 57 years old. No other cases had cognitive problems identified or reported during clinical examination and follow-up. | Neuropsychometric testing was performed in 3 individuals (XIII-3, XIII-4, and XIII-5) as well as case IX-5. The 2 affected individuals from a large SCA14 family (XIII-3, XIII-4) also reported cognitive dysfunction with difficulties in concentration and memory. Case XIII-3 is 57 years old. No other cases had cognitive problems identified or reported during clinical examination and follow-up. | Neuropsychometric testing was performed in 3 individuals (XIII-3, XIII-4, and XIII-5) as well as case IX-5. The 2 affected individuals from a large SCA14 family (XIII-3, XIII-4) also reported cognitive dysfunction with difficulties in concentration and memory. Case XIII-3 is 57 years old. No other cases had cognitive problems identified or reported during clinical examination and follow-up. | Neuropsychometric testing was performed in 3 individuals (XIII-3, XIII-4, and XIII-5) as well as case IX-5. The 2 affected individuals from a large SCA14 family (XIII-3, XIII-4) also reported cognitive dysfunction with difficulties in concentration and memory. Case XIII-3 is 57 years old. No other cases had cognitive problems identified or reported during clinical examination and follow-up. | Neurophysiological testing was performed in 3 other individuals (XIII-5, XIII-6, and XIII-7) also reported cognitive dysfunction with difficulties in concentration and memory. Case XIII-3 is 57 years old. No other cases had cognitive problems identified or reported during clinical examination and follow-up. | Neurophysiological testing was performed in 3 other individuals (XIII-5, XIII-6, and XIII-7) also reported cognitive dysfunction with difficulties in concentration and memory. Case XIII-3 is 57 years old. No other cases had cognitive problems identified or reported during clinical examination and follow-up. | Neurophysiological testing was performed in 3 other individuals (XIII-5, XIII-6, and XIII-7) also reported cognitive dysfunction with difficulties in concentration and memory. Case XIII-3 is 57 years old. No other cases had cognitive problems identified or reported during clinical examination and follow-up. | Neurophysiological testing was performed in 3 other individuals (XIII-5, XIII-6, and XIII-7) also reported cognitive dysfunction with difficulties in concentration and memory. Case XIII-3 is 57 years old. No other cases had cognitive problems identified or reported during clinical examination and follow-up. | Neurophysiological testing was performed in 3 other individuals (XIII-5, XIII-6, and XIII-7) also reported cognitive dysfunction with difficulties in concentration and memory. Case XIII-3 is 57 years old. No other cases had cognitive problems identified or reported during clinical examination and follow-up. | Neurophysiological testing was performed in 3 other individuals (XIII-5, XIII-6, and XIII-7) also reported cognitive dysfunction with difficulties in concentration and memory. Case XIII-3 is 57 years old. No other cases had cognitive problems identified or reported during clinical examination and follow-up.
**Discussion**

We studied a large cohort (n = 194) of mainly pure, autosomal dominant cerebellar ataxia cohort negative for trinucleotide repeats and identified 13 families with disease-causing mutations in PRKCG with a variable spectrum of disease phenotype and severity. Our data suggests that PRKCG mutations have a frequency of 6.7% (13/194). Previous studies showed SCA14 frequencies varying 1.5% to 7.5% in different ethnic groups.1-3 Also, early studies screened only parts of the gene, therefore some mutations may have been missed.2

In the 13 families with PRKCG mutations, we identified 10 unique pathogenic variants suggesting that recurrent PRKCG mutations are infrequent. All mutations are missense variants and are located within a functional domain. The majority of mutations are located in the regulatory C1 domain, consistent with previous reported data. The exact mechanism leading to disease in SCA14 is still unknown, and the simplistic loss-of-function hypothesis would not fully explain the autosomal dominant inheritance in the context of the Protein kinase C gamma (PKCγ) knockout mouse that had only a mild ataxia and did not show any morphological changes in the cerebellum.18,19 In vivo experiments show that mutations in the C1 domain decrease membrane binding, membrane retention time, and substrate phosphorylation, resulting in sustained high levels of intracellular Ca²⁺ upon cell stimulation and aberrant intracellular signalling.20 However, mutations in the catalytic domain showed an exaggerated inhibitory effect of Ca²⁺ entry in mutant cells when compared with wild type and Ca²⁺ influx was completely blocked.20 Therefore, it is becoming more clear that both sustained high Ca²⁺ influx as well as inhibition of Ca²⁺ influx is involved in SCA14 pathology depending on the functional domain that is affected. Interestingly, it was shown recently that mutations in the catalytic but not in the regulatory domain also show inhibition of the dendritic development in addition to a different pattern of the enzymatic activity.21 These findings together with the difference in PKCγ biological activity both in vitro and in vivo cell assays show that mutations located in different functional domains lead to disease through different mechanisms with a mutation-specific SCA14-resulting phenotype.20,22,23 Although less frequent, mutations in the catalytic domain have been described to cause a more complicated SCA14.2,20,24 Clinically, these mutations have been associated with a wider age of onset (childhood until late 60s) and a more complex phenotype including higher rate of cognitive dysfunction, myoclonus, dystonia, and reduced vibration sense (Table 2). In our study, the genotype-phenotype correlation confirms that the novel missense variant c.1372G>A (p.Ala458Thr) located in the catalytic domain produced the most complex and severe phenotype. We would like to highlight the unusual presentation of ataxia associated with a severe, time-deferred dystonic component and a severe peripheral neuropathy in the context of the missense p.Ala458Thr. Dystonia has been previously reported in SCA14 mainly described as focal, task-induced dystonia.9 Our case series extends the phenotype and supports the association of ataxia and dystonia in SCA14. To our knowledge, severe peripheral neuropathy has not been previously formally associated with SCA14; however, several cases of reduced vibration loss were reported in mutations affecting the regulatory domain (Table 2). The association with severe peripheral neuropathy needs to be confirmed in larger cohorts.

Our data suggest that in the majority of cases, SCA14 has an onset from childhood to early adulthood, is slowly progressive, and is rarely associated with severe disability, consistent with previous reports.25 However, about 12% of cases presented with a late-onset cerebellar ataxia (>50 years old). The most common genetic conditions with similar presentation in this age group are usually caused by CAG repeat expansions SCAs (SCA 1, 2, 3, and 6) and Friedreich’s ataxia that require different approaches for molecular diagnosis. Importantly, although our cohort had a long mean disease duration (18 years), the mean SARA score was consistent with moderate severity, supporting a slow disease progression course. The most severe SARA score was 22.5 in a patient who had the disease for more than 50 years. Therefore, an autosomal dominant cerebellar ataxia with normal SCA repeats, especially when slow progression and predominantly pure phenotype is predominant, should alert the physician to test for PRKCG mutations. We show that next generation sequencing can further contribute to diagnosis in cases of late-onset cerebellar ataxia where the repeats are within normal ranges.

More than a third of the patients in our study presented with a complex ataxia phenotype composing of severe focal and/or task-induced dystonia, severe peripheral neuropathy, parkinsonism, myoclonus, tremor, and/or pyramidal syndrome. This is consistent with previous reports of complex cases of ataxia associated with dystonia, myoclonus, tremor, and pyramidal syndrome secondary to PRKCG mutations.3,9,26 In our cohort, myoclonus was identified in 3 cases. This was clinically characterized as occasional and mild, not requiring any treatment. Myoclonus was identified early in the disease and remained mild in the advanced cases. Unfortunately, none of the patients reported having undergone electrophysiological recording, and we are unable to comment further on this aspect; therefore, further studies need to assess myoclonus as it may be more frequent than previously reported.

We report 1 case with a combination of mild parkinsonism (presenting a stooped posture, gait freeing, rigidity, and bradykinesia) in addition to cerebellar ataxia. Interestingly, the rat animal model of PRKCG also exhibits a parkinsonian phenotype.22 Parkinsonism is rare and
mild in SCA14,2,24 Our case as well as the Dutch9 and French families2,24 presented with subtle parkinsonian syndrome in their early 20s that has not progressed with the disease and did not require Levodopa treatment. The combination of ataxia and parkinsonism is frequent in neurodegenerative ataxias28; however, the combination of autosomal dominant SCA and parkinsonism is mainly observed in a parkinsonian form of SCA3 and sometimes in SCA2,28,29 where the parkinsonism is present early in the disease. In such cases, clinical differential diagnosis is challenging and only genetic investigation can provide a definite diagnosis. The sporadic neurodegenerative cerebellar ataxias with parkinsonism, such as multiple system atrophy, present usually with a late-onset and a faster disease progression and are associated with autonomic dysfunction.

In addition, cognitive impairment is only rarely reported in SCA14, and if cognition is affected, only minimal severity is reported,30 which was mirrored in our series. However, a formal neuropsychology assessment was conducted in symptomatic cases only limiting our ability to characterize this further. We would like to stress that all SCA14 cases that reported cognitive impairment were before the age of 50 years, and this complaint is not attributed to age-related associated disorders at present. Cognitive impairment has been reported in other genetic forms of SCA and is not only restricted to SCA14;21 our study and previous reports warrant a further uniformed and systematic evaluation to validate these results.

Therefore, our data suggests that SCA14 diagnosis in complex phenotypes should be considered in patients with slowly progressive autosomal dominant cerebellar ataxias, particularly when myoclonus, dystonia, or cognitive impairment is present in the absence of polyglutamine expansions. Furthermore, a very mild severity and a slow progression of the additional features such as parkinsonism and myoclonus in SCA14 can help differentiate them from other forms of sporadic neurodegenerative disorders, such as multiple system atrophy (MSA).

Conclusion

We present one of the largest SCA14 cohorts of patients reported contributing with novel variants and supporting the distinct phenotype spectrum with specific cellular defects resulting from different types of PRKCG mutations. Our cases extend the phenotype and support the association of ataxia and severe dystonia in SCA14. The association with severe peripheral neuropathy needs confirmation in larger cohorts.

Acknowledgments: We would like to thank the patients for their participation in this study. This study was supported by the Medical Research Council (MRC, UK MR/J004758/1, G0802760, G1001253), The Wellcome Trust in equipment and strategic award (Synaptopathies) funding (WT093205/MA and WT104053/Z/14/Z), The Brain Research Trust, The MSA Trust, the European Union Seventh Framework Programme FP7/2007-2013 under grant agreement number 2012-305121 (Neuromics), Ataxia UK, British Neurological Surveillance Unit, the National Institute for Health Research, University College London Hospitals, and the Biomedical Research Centre.

References
14 increase kinase activity and alter membrane targeting. Brain 2005;128:436-442.
23. Doran G, Davies KE, Talbot K. Activation of mutant protein kinase C gamma leads to aberrant sequestration and impairment of its cellular function. Biochem Biophys Res Commun 2008;372:447-453.
24. Stevanin G, Hahn V, Lohmann E, et al. Mutation in the catalytic domain of protein kinase C gamma and extension of the phenotype associated with spinocerebellar ataxia type 14. Arch Neurol 2004;61:1242-1248.
25. Ganos C, Zittel S, Minnerop M, et al. Clinical and neurophysiological profile of four German families with spinocerebellar ataxia type 14. Cerebellum 2014;13:89-96.
26. Visser JE, Bloem BR, van de Warrenburg BP. PRKCG mutation (SCA-14) causing a Ramsay Hunt phenotype. Mov Disord 2007;22:1024-1026.
27. Craig NJ, Duran Alonso MB, Hawker KL, et al. A candidate gene for human neurodegenerative disorders: a rat PKC gamma mutation causes a Parkinsonian syndrome. Nat Neurosci 2001;4:1061-1062.
28. Schols L, Peters S, Szynanski S, et al. Extrapyramidal motor signs in degenerative ataxias. Arch Neurol 2000;57:1493-1500.
29. Gwinn-Hardy K, Singleton A, O’Suilleabhain P, et al. Spinocerebellar ataxia type 3 phenotypically resembling parkinson disease in a black family. Arch Neurol 2001;58:296-269.
30. Wedding IM, Koht J, Dietrichs E, Landro NI, Tallaksen CM. Cognition is only minimally impaired in Spinocerebellar ataxia type 14 (SCA14); a neuropsychological study of ten Norwegian subjects compared to intrafamilial controls and population norm. BMC Neurol 2013;13:1471-2377.
31. Najmabadi H, Hu H, Garshasi M, et al. Deep sequencing reveals 50 novel genes for recessive cognitive disorders. Nature 2011;478:57-63.
32. Al-Maghtheh M, Vithana EN, Inglehearn CF, Moore T, Bird AC, Bhattacharya SS. Segregation of a PRKCG mutation in two RP11 families. Am J Hum Genet 1998;62:1248-1252.
33. Asai H, Hirano M, Shimada K, et al. Protein kinase C gamma, a protein causative for dominant ataxia, negatively regulates nuclear import of recessive-ataxia-related aprataxin. Hum Mol Genet 2009;18:3533-3543.
34. Ji J, Hassler ML, Shimobayashi E, Paka N, Streit R, Kapfhammer JP. Increased protein kinase C gamma activity induces ParkinJe cell pathology in a mouse model of spinocerebellar ataxia 14. Neurobiol Dis 2014;70:1-11.

Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher’s website.